Daytime SHP2 inhibitor dosing, when immune cell numbers are elevated, shrinks neurofibromas
{{output}}
Loss of NF1 in Schwann cells leads to activation of the RAS-MAPK pathway, followed by immune cell recruitment and development of benign nerve tumors (PNFs). MEK inhibitors, which shrink most PNFs, also reduce tumor-associated myeloid cells. We tested whether S... ...
